News

Adjuvant Cetuximab Fails to Boost FOLFOX in Stage III Colon Cancer

Publish date: July 2, 2012

 

AT THE WORLD CONGRESS ON GASTROINTESTINAL CANCER

Merck Serono and Sanofi-Aventis provided grants to fund the trial. Dr. Taieb has received consultancy and advisory board honoraria from Merck. Dr. Ducreux has received consultancy fees from Merck Serono and Roche.

Pages

Recommended Reading

Duodenal GIST Responds to Surgery, Imatinib
MDedge Surgery
Wide Disparity in Appendicitis Costs Observed
MDedge Surgery
Lymphadenectomy Underused in GI Cancer Surgery
MDedge Surgery
MRSA Nasal Colonization Predicts MRSA Site Infection in GI Surgery
MDedge Surgery
Laparoscopy Tops Open Resection for Most Gastric Tumors
MDedge Surgery
Gastric Bypass Induces Diabetes Remission in Mildly Obese
MDedge Surgery
Antireflux Procedures Increasingly Performed at Low-Volume Centers
MDedge Surgery
Blocking GI Acid Linked to Lower Pouchitis Risk
MDedge Surgery
Ventral Hernia Repair Incurs Overall Financial Losses
MDedge Surgery
Pancreatic Surgery Scorecard Aligns With IOM Quality Metrics
MDedge Surgery